GlassScriptPhysician profile
Michael J Wilcox
NPI 1881668655
$4,871.20
in general payments reported to CMS, 2019-2025
34 companies · $974 in 2025
The $974 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $219 · 2021: $506 · 2022: $986 · 2023: $634 · 2024: $1,067 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.51 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $631.69 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.61 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $467.57 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $329.93 | 2019-2025 | |
| Pfizer INC. | $269.07 | 2022-2025 | |
| Glaxosmithkline, LLC. | $220.53 | 2019-2023 | Shingrix, Bexsero, Arexvy |
| Abbott Laboratories | $157.45 | 2022 | |
| Exact Sciences Corporation | $154.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $153.62 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $147.31 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $118.56 | 2024-2025 | Korlym |
| Sanofi Pasteur INC. | $84.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $81.95 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Dexcom, INC. | $52.20 | 2024-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $51.05 | 2019-2022 | |
| Lilly USA, LLC | $37.56 | 2022-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $36.39 | 2021-2023 | Yupelri |
| Lundbeck LLC | $34.14 | 2024 | Rexulti |
| Philips North America LLC | $32.71 | 2024-2025 | Mcot, (Ck4) Mcot |
| Amgen INC. | $30.78 | 2019-2025 | Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $28.39 | 2022 | |
| Astellas Pharma US INC | $27.37 | 2023 | Veozah |
| Biogen, INC. | $26.70 | 2025 | Leqembi |
| Kowa Pharmaceuticals America, INC. | $24.28 | 2021 | |
| Novo Nordisk INC | $22.12 | 2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $19.07 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.96 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $17.31 | 2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $16.00 | 2021 | |
| Shionogi INC | $15.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.46 | 2022 | |
| Allergan, INC. | $13.04 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.